Join Siemens Healthineers and Roma Levy, MS, to learn about the first blood test granted De Novo marketing authorization by the FDA for prognosis in advanced fibrosis due to NASH. In this webinar, Ms. Levy will explain how ELF can enable accessible, effortless testing that can simplify and accelerate the identification of patients with advanced fibrosis due to NASH who may benefit most from potentially life-saving preemptive care; an important first -step in turning the tide against the liver’s silent killer.
Speaking on these findings, H. Roma Levy, MS, senior clinical expert at Siemens Healthineers, will help you gain a better understanding of:
- NAFLD and NASH pathophysiology and epidemiology
- How the ELF test addresses the unmet need for prognostic NASH evaluation
- Understanding ELF test interpretation
- Assay characteristics
Roma Levy received her Bachelor of Arts degree in biology from Northwestern University and a Master of Science degree in molecular biology with an emphasis in chronobiology (in which she conducted independent research investigating the genetic control of circadian rhythms) at University of California, Santa Cruz.
As a medical writer and educator for Siemens Healthineers, over the past 17 years Ms. Levy has written, co-authored, or supported multiple articles, abstracts, posters, and clinical educational presentations in diverse areas, including sepsis, immunology, and infectious disease (including the underlying pathophysiology behind cytokine storm associated with COVID-19), liver fibrosis, endocrinology, fetal medicine, cardiology, and opioid addiction. Ms. Levy recently assumed the position of clinical expert for liver fibrosis and is actively involved in supporting all aspects of clinical education and publication for the ELF test, globally.
